Sunday, July 6, 2025 7/6/2025

MYCT1 as a moderator for signaling between human HSC and their niche

Award Number: R01HL162408
ORGANIZATION: NATIONAL HEART, LUNG, & BLOOD INSTITUTE
OPDIV: NIH
AWARD CLASS: DISCRETIONARY
AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)
PERIOD OF PERFORMANCE START DATE: 04/01/2022
PERIOD OF PERFORMANCE END DATE: 02/28/2025

Group Awards By:

View Award Description

MYCT1 as a moderator for signaling between human HSC and their niche - SUMMARY Hematopoietic stem cells (HSC) need to integrate microenvironmental cues to switch their fate between quiescence, self-renewal, and differentiation, thereby sustaining hematopoiesis through life. However, the molecular programs governing HSC stemness become grossly dysregulated during culture, hindering our ability to expand functional HSCs for treating hematological diseases. Our data uncovered MYCT1 (Myc target 1) as human HSC regulatory factor that is critical for their expansion and engraftment, but becomes suppressed during differentiation and culture. We found that MYCT1 localizes in endosomes, interacts with vesicle components and signaling receptors with critical functions in HSCs (e.g. TGFBR1 and 2), and controls the rate of endocytosis, which modulates cell signaling and must be tightly regulated to maintain HSC stemness. Many genes dysregulated upon MYCT1 knockdown (KD) are linked to HSC division and self-renewal. We hypothesize that MYCT1 governs HSC stemness and their ability to balance between fate options by fine-tuning multiple signaling cues through the control of endocytosis. We have created a toolbox of MYCT1 knockdown and overexpression vectors, including various MYCT1 deletion mutants, that can be used in primary human HSPCs as well as HSC- like and endothelial cell line models to investigate MYCT1 mechanism of action. We will investigate how MYCT1- mediated control of endocytosis affects signaling in HSCs, and how this influences HSC cell-fate decisions including quiescence and asymmetric vs symmetric division. We will then assess if rescuing MYCT1 regulated processes improves the function of cultured human HSC, including those expanded using MLLT3 overexpression. Our work may open up new strategies to maintain HSC transplantability during ex vivo expansion and ultimately help broaden HSC clinical applications.


Issue Date FY	Funding FY	Legal Entity Name	Legal Entity Address	Legal Entity City	Legal Entity State	Legal Entity Zip Code	Legal Entity COUNTY	Legal Entity COUNTRY	Assistance Listing	Award Code	Budget Year	Action Date	Action Type	Action Amount

Issue Date FY: 2024 ( Subtotal = $312,000 )
2024	2024	UNIVERSITY OF CALIFORNIA, LOS ANGELES	10889 WILSHIRE BLVD STE 700	LOS ANGELES	CA	90024	LOS ANGELES	USA	Blood Diseases and Resources Research	000	3	3/18/2024	NON-COMPETING CONTINUATION	$312,000
														Subtotal = $312,000

Issue Date FY: 2023 ( Subtotal = $312,000 )
2023	2023	UNIVERSITY OF CALIFORNIA, LOS ANGELES	10889 WILSHIRE BLVD STE 700	LOS ANGELES	CA	90024	LOS ANGELES	USA	Blood Diseases and Resources Research	000	2	2/27/2023	NON-COMPETING CONTINUATION	$312,000
														Subtotal = $312,000

Issue Date FY: 2022 ( Subtotal = $312,000 )
2022	2022	UNIVERSITY OF CALIFORNIA, LOS ANGELES	10889 WILSHIRE BLVD STE 700	LOS ANGELES	CA	90024	LOS ANGELES	USA	Blood Diseases and Resources Research	000	1	3/16/2022	NEW	$312,000
														Subtotal = $312,000

Grand Total All Awards = $936,000

Top

All Categories

About

Search

Reports

Data Submission

Award Information

MYCT1 as a moderator for signaling between human HSC and their niche

Award Number: R01HL162408

ORGANIZATION: NATIONAL HEART, LUNG, & BLOOD INSTITUTE

OPDIV: NIH

AWARD CLASS: DISCRETIONARY

AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)

PERIOD OF PERFORMANCE START DATE: 04/01/2022

PERIOD OF PERFORMANCE END DATE: 02/28/2025

Federal Websites

Department of Health & Human Services

HHS Operating Divisions

HHS Staff Divisions

Download A Document Viewer